YouTube video by Martyn Lucas Investor

Grail has teamed up with telehealth company Hims & Hers to boost access to its recently filed Galleri blood test for cancer screening

Novo Nordisk's battered stock enjoyed a reprieve after Hims & Hers abandoned plans to launch a compounded version of the new Wegovy pill.

The telehealth firm is running an ad during Sunday’s game pitching its platform as a way to access health services enjoyed by the wealthy, such as a controversial test to detect cancer with a simple b...

NVO LLY hereremove ads CVSCI hereremove ads hereremove ads Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Andrew Dudum is hitting back hard at the FTC's lawsuit over health data sharing, calling it a publicity move after settlement talks fell apart. With an $86M quarterly loss and a major pivot away from compounded weight-loss drugs, the company has plenty riding on how this fight plays out.

Andrew Dudum is hitting back hard at the FTC's lawsuit over health data sharing, calling it a publicity move after settlement talks fell apart. With an $86M quarterly loss and a major pivot away from compounded weight-loss drugs, the company has plenty riding on how this fight plays out.

The telehealth company beat revenue expectations and raised its full-year outlook to $3.1–3.3 billion, but a costly pivot away from compounded GLP-1 drugs helped swing it to an $86 million quarterly loss. Throw in an FTC lawsuit over data privacy and shady billing practices, and it's a complicated moment for one of the hottest names in weight loss care.

Hims & Hers was sued on July 29, 2026, by the FTC, joined by Utah and California through Los Angeles County Counsel, over allegations that it shared consumers’ sensitive health data with Meta and Snap for advertising and used deceptive billing and cancellation practices. The company had already disclosed in its 2025 Annual Report that the FTC sent it a…

FTC, California and Utah sued telehealth firm Hims & Hers, alleging it shared sensitive health data with Meta and Snap and used deceptive subscription billing.

US digital health provider Hims & Hers Health has acquired Eucalyptus, the parent company of Juniper, to expand its preventative healthcare reach to UK patients. It will focus on sexual health…

Key takeaways Farmaceutgigant Novo Nordisk heeft haar rechtszaak tegen telezorgaanbieder Hims & Hers laten vallen. Volgens Nordisk verkocht Hims & Hers goedkopere- en niet-goedgekeurde kopieën van het populaire afslankmiddel Wegovy. Na overleg hebben de twee bedrijven een overeenkomst gesloten. Hims & Hers zal vanaf nu de medicijnen van Novo Nordisk op haar platform verkopen. Als […]

Key takeaways Farmaceutische gigant Novo Nordisk onderneemt juridische stappen tegen Hims & Hers, een online aanbieder van telegezondheidszorg. Hims & Hers zou goedkopere en niet-goedgekeurde kopieën van het populaire afslankmedicijn Wegovy op de markt brengen. “Dit is een complete schijnvertoning”, vertelt John Kuckelman, Novo’s algemeen juridisch adviseur in een interview met CNBC. “Hun medicijnen zijn […]

A U.S. senator is asking the FDA how it will enforce regulations on pharmaceutical advertising after it let go of numerous employees from the office that oversees the issue.

BofA kept Hims & Hers' price target at $23 on Mar 26, 2026; the move underscores continued scrutiny of ARPU and CAC despite sector growth projections (Investing.com).